GlobeNewswire Inc | Oct 5, 2021 07:30AM EDT

October 05, 2021

DURHAM, N.C., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that senior leadership will present at seven scientific and industry events in October 2021.

Weve made remarkable progress with our human acellular vessel (HAV) and continue to advance the HAV through multiple late-stage clinical and preclinical trials, said Laura Niklason, M.D., Ph.D., Founder, President and Chief Executive Officer of Humacyte. Were pleased to have an opportunity to connect with leaders and innovators in the industry at upcoming conferences, and look forward to sharing data and findings that highlight the potential of HAV to be a valuable tool for many diseases and conditions.

The details of the events are as follows:

Cell & Gene Meeting on the MesaSession: Company presentationTitle: The Commercial-Scale LUNA200 System Enables Production of Universally Implantable Regenerative Human TissueThe presentation will highlight Humacytes corporate and clinical achievements to date, as well as the three-month data from its Phase 2 comparability trial that evaluated product from the commercial-scale LUNA200 system which currently supplies HAVs for pivotal and ongoing clinical trial programs.Location: Carlsbad, CADate / time: Thursday, Oct. 14, 2021, 9:30-9:45 a.m. PDTPresenter: Dale Sander, Chief Corporate Development Officer and Chief Financial Officer, Humacyte

UC San Diego Inaugural Sanford Stem Cell SymposiumSession: Bioengineering Stem CellsTitle: Bioengineering Stem Cells in the Lung The presentation will discuss key design criteria for whole lung regeneration, and recent efforts at reconstituting the lung alveolus, which is the main location for the exchange of oxygen and carbon dioxide in the lungs.Location: Virtual webcastDate / time: Thursday, Oct. 14, 2021, 2:20-2:40 p.m. PDT, followed by a live panel discussion Presenter: Laura Niklason, M.D., Ph.D., Founder, President and Chief Executive Officer, Humacyte

6th Bioengineering & Translational Medicine ConferenceSession: 4 Title: Stem Cells and Regenerative Medicine The keynote presentation will cover Humacytes progress in clinical vascular regeneration, as well as preclinical updates in utilizing the HAV to deliver pancreatic islets, as well as preclinical updates in whole lung regeneration.Location: Virtual webcastDate / time: Tuesday, Oct. 19, 2021, 12:35-1:15 p.m. EDTPresenter: Laura Niklason, M.D., Ph.D., Founder, President and Chief Executive Officer, Humacyte

Paris Vascular InsightsSession: Dialysis Modalities: What, When, Why and in WhomTitle: Bioengineered Acellular Vessels for Use in Vascular Access and Arterial RepairThe presentation will summarize Humacytes clinical programs in vascular access and arterial recontstruction, repair and replacement, highlighting the HAVs utility across multiple vascular applications.Location: Virtual webcastDate / time: Thursday, Oct. 21, 2021, 12 p.m. CESTPresenter: Jeffrey Lawson, M.D., Ph.D., Chief Surgical Officer, Humacyte

18th World Congress of the International Pancreas and Islet Transplantation Association (IPITA)Session: Bio-EngineeringTitle: Novel Approach in Pancreatic Islet Transplantation: Acellular VesselThe presentation will highlight data on laboratory and preclinical models demonstrating the potential to engineer a biovascular pancreas to deliver islet cells to produce insulin in Type 1 diabetic patients. Location: Virtual webcastDate / time: Friday, Oct. 22, 2021, 11:30-12:45 p.m. GMTPresenter: Jeffrey Lawson, M.D., Ph.D., Chief Surgical Officer, Humacyte

South American Society of Vascular Surgery Session: Vascular Surgery and VASA SymposiumTitles:

-- Bioengineered Vessel Creation - History and InnovationThe presentation will share the scientific journey surrounding the creation of a bioengineered blood vessel suitable for use in dialysis access and other vasculary applications such as arterial repair and replacement.

-- The Use of the HAV in Peripheral Vascular Disease and Dialysis PatientsThe presentation will highlight the clinical use of the HAV across multiple clinical trial programs in vascular access and peripheral arterial disease.

Location: Mexico City, MexicoDate / time: Thursday, Oct. 28, 2021Presenter: Jeffrey Lawson, M.D., Ph.D., Chief Surgical Officer, Humacyte

Vascular Biology 2021Session: Vascular Therapeutics Title: Engineering Arterial and Pulmonary VasculatureThe presentation will focus on systemic vascular engineering that is done by Humacyte for the manufacturing of HAVs, as well as preclinical efforts at regenerating the microvessels of tissue engineered whole lung constructs.Location: Virtual webcastDate / time: Friday, Oct. 29, 2021, 12-12:20 p.m. EDTPresenter: Laura Niklason, M.D., Ph.D., Founder, President and Chief Executive Officer, Humacyte

About HAVHuman Acellular Vessels (HAV) are engineered off-the-shelf replacement vessels initially being developed for vascular repair, reconstruction and replacement. HAV is intended to overcome long-standing limitations in vessel tissue repair and replacement it can be manufactured at commercial scale, it eliminates the need for harvesting a vessel from a patient, and clinical evidence suggests that it is non-immunogenic, infection-resistant, and can become durable living tissue. HAV is currently being evaluated in two Phase 3 trials in AV access and a Phase 2/3 trial for vascular trauma, and has been used in more than 460 patient implantations. It is the first product to receive Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration, and has also received FDA Fast Track designation.

About HumacyteHumacyte, Inc., (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacytes initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Pre-clinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacytes HAVs were the first product to receive the FDAs Regenerative Medicine Advanced Therapy (RMAT) expedited review designation and received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visitwww.Humacyte.com.

Humacyte Investor Contact:investors@humacyte.com

Humacyte Media Contact: media@humacyte.com